| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2183 | 2017 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1662 | 2018 |
| ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV P Ferenci, D Bernstein, J Lalezari, D Cohen, Y Luo, C Cooper, E Tam, ... New England Journal of Medicine 370 (21), 1983-1992, 2014 | 1011 | 2014 |
| Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin S Zeuzem, IM Jacobson, T Baykal, RT Marinho, F Poordad, M Bourlière, ... New England Journal of Medicine 370 (17), 1604-1614, 2014 | 786 | 2014 |
| A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel M Cornberg, HA Razavi, A Alberti, E Bernasconi, M Buti, C Cooper, ... Liver International 31, 30-60, 2011 | 595 | 2011 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 564 | 2014 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 488 | 2022 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 416 | 2014 |
| Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke DP Hopkins, PA Briss, CJ Ricard, CG Husten, VG Carande-Kulis, ... American journal of preventive medicine 20 (2), 16-66, 2001 | 335 | 2001 |
| Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ... The lancet Gastroenterology & hepatology 2 (5), 325-336, 2017 | 328 | 2017 |
| Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients RN Gunson, D Shouval, M Roggendorf, H Zaaijer, H Nicholas, ... Journal of Clinical Virology 27 (3), 213-230, 2003 | 283 | 2003 |
| Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis T Asselah, KV Kowdley, N Zadeikis, S Wang, T Hassanein, Y Horsmans, ... Clinical Gastroenterology and Hepatology 16 (3), 417-426, 2018 | 281 | 2018 |
| Strategies to manage hepatitis C virus (HCV) disease burden H Wedemeyer, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, ... Journal of viral hepatitis 21, 60-89, 2014 | 278 | 2014 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 223 | 2022 |
| State-of-the-art review on deep learning in medical imaging M Biswas, V Kuppili, L Saba, DR Edla, HS Suri, E Cuadrado-Godia, ... Frontiers in Bioscience-Landmark 24 (3), 380-406, 2019 | 219 | 2019 |
| Symtosis: A liver ultrasound tissue characterization and risk stratification in optimized deep learning paradigm M Biswas, V Kuppili, DR Edla, HS Suri, L Saba, RT Marinhoe, ... Computer methods and programs in biomedicine 155, 165-177, 2018 | 208 | 2018 |
| Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study D Razavi-Shearer, I Gamkrelidze, C Pan, J Jia, T Berg, R Gray, YS Lim, ... The lancet Gastroenterology & hepatology 8 (10), 879-907, 2023 | 196 | 2023 |
| High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1–6 patients without cirrhosis M Puoti, GR Foster, S Wang, D Mutimer, E Gane, C Moreno, TT Chang, ... Journal of hepatology 69 (2), 293-300, 2018 | 182 | 2018 |
| Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe AD Marshall, EB Cunningham, S Nielsen, A Aghemo, H Alho, ... The lancet Gastroenterology & hepatology 3 (2), 125-133, 2018 | 173 | 2018 |
| Hepatitis C, stigma and cure RT Marinho, DP Barreira World Journal of Gastroenterology: WJG 19 (40), 6703, 2013 | 167 | 2013 |
João Miguel SanchesInstitute for Systems and Robotics (ISR/IST), LARSyS, Instituto Superior Técnico, Univ Lisboaبريد إلكتروني تم التحقق منه على tecnico.ulisboa.pt
